Pentobarbital/Phenytoin Inj

Verify with FDA CVM →

98 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
98
Total Reports
79
Deaths Reported
8060.0%
Death Rate

Active Ingredients

Pentobarbital/Phenytoin Inj

Administration Routes

IntravenousUnknownSubcutaneousOtherTopicalIntraperitonealRespiratory (Inhalation)OphthalmicIntramuscularOral

Species Affected

Dog 58
Cat 15
Human 11
Unknown 7
Horse 5
Other Birds 1
Duck 1

Most Affected Breeds

Unknown 19
Domestic Shorthair 11
Dog (unknown) 8
Crossbred Canine/dog 7
Shepherd Dog - German 4
Mixed (Dog) 4
Retriever - Golden 4
Retriever - Labrador 3
Shih Tzu 3
Horse (unknown) 2

Most Reported Reactions

INEFFECTIVE, EUTHANASIA 60
Overdose 39
Unrelated death 33
Vocalisation 24
Lack of efficacy - NOS 18
Agitation 10
Death by euthanasia 9
INEFFECTIVE, DELAYED EFFECT 8
Pain NOS 7
Accidental exposure 7
Solution, Abnormal 5
Drug administration error 5

Outcome Breakdown

Euthanized
79 (86.8%)
Ongoing
8 (8.8%)
Recovered/Normal
3 (3.3%)
Outcome Unknown
1 (1.1%)

Data Summary

Metric Value
Total adverse event reports 98
Reports involving death 79
Case-fatality rate (reported events) 8060.0%
Distinct species in reports 7
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Pentobarbital/Phenytoin Inj Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 98 adverse event reports referencing Pentobarbital/Phenytoin Inj, including 79 reports in which the animal died — a 8060.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Pentobarbital/Phenytoin Inj. Reported administration routes include Intravenous, Unknown, Subcutaneous, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Pentobarbital/Phenytoin Inj reports are Dog (58 reports), Cat (15 reports), Human (11 reports), with Dog accounting for the largest share. Within those species, Unknown (19), Domestic Shorthair (11), Dog (unknown) (8) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Pentobarbital/Phenytoin Inj are INEFFECTIVE, EUTHANASIA (60), Overdose (39), Unrelated death (33), Vocalisation (24). Of the 91 reports with a coded outcome, Euthanized is the leading category at 86.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Pentobarbital/Phenytoin Inj.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial